A Phase 2 interventional study of Placebo and Belimumab 1 mg/kg in Lupus Erythematosus, Systemic, sponsored by Human Genome Sciences Inc.. Completed at 62 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 8th largest by enrollment, is the only one that started in 2003, is one of 8 in phase 2, and was the 1st registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 449 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc. is the lead sponsor of 23 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 8th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2003, is one of 7 in phase 2, and was the 1st registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.
The purpose of this study is to evaluate the safety and efficacy of three different doses of belimumab (1 mg/kg, 4 mg/kg, and 10 mg/kg), administered in addition to standard therapy, compared to placebo plus standard therapy in patients with active SLE disease. Patients were randomly assigned, following stratification by the screening SELENA SLEDAI score (4 to 7 versus ≥ 8), to 1 of the 4 study arms (3 active arms and 1 placebo arm plus standard therapy for SLE). All patients were to be dosed on Days 0, 14, and 28, then every 28 days for the remainder of 52 weeks. Patients completing the 52-week period could enter a 24-week open-label extension; belimumab patients received the same dose or were switched to 10 mg/kg at the investigator's discretion and former placebo patients received belimumab 10 mg/kg.
Primary Inclusion Criteria
Primary Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Belimumab 1 mg/kg
Drug: Belimumab 4 mg/kg
Drug: Belimumab 10 mg/kg
Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Drug page: Belimumab
Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Also known as: LymphoStat-B®, BENLYSTA®
Drug page: Belimumab
Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Also known as: LymphoStat-B®, BENLYSTA®
Drug page: Belimumab
Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
Also known as: LymphoStat-B®, BENLYSTA®
Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare.
Time frame: Baseline, 24 weeks
Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)
The SLE Flare Index categorized SLE flare as "mild or moderate" or "severe" based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).
Time frame: 0 to 52 weeks
Percentage Change From Baseline in SELENA SLEDAI Score at Week 52
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare
Time frame: Baseline, 52 weeks
Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score.
Time frame: Baseline and every 4 to 8 weeks through Week 52
Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52
The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.
Time frame: Baseline, 52 weeks
Area Under the Curve (AUC) of BILAG Score at Week 52
The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score.
Time frame: Baseline and every 4 to 8 weeks through Week 52
Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks
SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit.
Time frame: 0 to 52 weeks
Percentage of Patients With a Reduction in Prednisone Dose
Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline.
Time frame: Baseline, weeks 40 to 52
Adverse Events (AE) Overview
Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).
Time frame: Up to 84 weeks
| Milestone | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Started | 113 | 114 | 111 | 111 |
| Completed | 93 | 87 | 94 | 90 |
| Not completed | 20 | 27 | 17 | 21 |
| Withdrew: Adverse event | 5 | 8 | 4 | 8 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 7 | 11 | 7 | 7 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Lack of compliance | 6 | 3 | 3 | 3 |
| Milestone | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Started | 0 | 19 | 24 | 302 |
| Completed | 0 | 19 | 23 | 279 |
| Not completed | 0 | 0 | 1 | 23 |
| Withdrew: Adverse event | 0 | 0 | 1 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 9 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Lack of compliance | 0 | 0 | 0 | 2 |
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare.
| percent change | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24. | -17.2 ± 5.1 | -23.3 ± 4.4 | -11.3 ± 5.4 | -23.7 ± 4.2 |
The SLE Flare Index categorized SLE flare as "mild or moderate" or "severe" based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).
| days | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index) | 83 (42 to 140) | 68 (39 to 146) | 61 (29 to 147) | 70 (29 to 154) |
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare
| percent change | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Percentage Change From Baseline in SELENA SLEDAI Score at Week 52 | -20.6 ± 5.2 | -29.7 ± 4.3 | -23.9 ± 7.3 | -27.9 ± 5.5 |
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score.
| ratio score*days | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52 | 317.3 ± 14.0 | 288.7 ± 12.5 | 320.3 ± 14.0 | 286.9 ± 13.0 |
The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.
| percent change | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52 | -19.1 ± 4.3 | -20.8 ± 4.3 | -26.5 ± 3.4 | -22.0 ± 4.3 |
The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score.
| ratio score*days | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Area Under the Curve (AUC) of BILAG Score at Week 52 | 315.4 ± 12.3 | 310.6 ± 12.0 | 300.4 ± 9.3 | 302.7 ± 12.3 |
SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit.
| days | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks | 78 (34 to 138) | 63 (54 to 110) | 84 (51 to 139) | 62 (33 to 108) |
Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline.
| percentatge of particpants | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Percentage of Patients With a Reduction in Prednisone Dose | 27.1 | 20.0 | 31.4 | 44.7 |
Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).
| percentage of participants | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Open-Label Extension Period: All Active |
|---|---|---|---|---|---|
| Percent of patients with at least 1 AE | 97.3 | 97.4 | 96.4 | 97.3 | 96.2 |
| Percent of patients with at least 1 SAE | 19.5 | 18.4 | 13.5 | 16.2 | 9.6 |
| Percent of patients with an AE resulting in death | 0 | 0.9 | 0 | 0.9 | 0 |
Collected over Up to 84 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Plus SOC | — | 22/113 (19.5%) | 103/113 (91.2%) |
| Belimumab 1 mg/kg Plus SOC | — | 21/114 (18.4%) | 107/114 (93.9%) |
| Belimumab 4 mg/kg Plus SOC | — | 15/111 (13.5%) | 100/111 (90.1%) |
| Belimumab 10 mg/kg Plus SOC | — | 18/111 (16.2%) | 105/111 (94.6%) |
| Open-label Extension Period: All Active | — | 33/345 (9.6%) | 312/345 (90.4%) |
| Event | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Open-label Extension Period: All Active |
|---|---|---|---|---|---|
| PancreatitisGastrointestinal disorders | 0/113 | 0/114 | 2/111 | 0/111 | 0/345 |
| CholelithiasisHepatobiliary disorders | 0/113 | 1/114 | 2/111 | 0/111 | 0/345 |
| ProteinuriaRenal and urinary disorders | 1/113 | 0/114 | 0/111 | 2/111 | 3/345 |
| Non-cardiac chest painGeneral disorders | 2/113 | 1/114 | 0/111 | 1/111 | 3/345 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 2/113 | 0/114 | 0/111 | 0/111 | 0/345 |
| CellulitisInfections and infestations | 0/113 | 2/114 | 1/111 | 0/111 | 1/345 |
| PneumoniaInfections and infestations | 1/113 | 2/114 | 1/111 | 0/111 | 0/345 |
| Transient ischaemic attackNervous system disorders | 0/113 | 2/114 | 1/111 | 1/111 | 1/345 |
| Angina pectorisCardiac disorders | 1/113 | 0/114 | 1/111 | 0/111 | 0/345 |
| Atrial fibrillationCardiac disorders | 0/113 | 0/114 | 1/111 | 0/111 | 0/345 |
| Event | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Open-label Extension Period: All Active |
|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 42/113 | 41/114 | 37/111 | 41/111 | 102/345 |
| Upper respiratory tract infectionInfections and infestations | 33/113 | 36/114 | 36/111 | 29/111 | 58/345 |
| HeadacheNervous system disorders | 27/113 | 29/114 | 31/111 | 35/111 | 50/345 |
| FatigueGeneral disorders | 34/113 | 27/114 | 33/111 | 27/111 | 72/345 |
| NauseaGastrointestinal disorders | 27/113 | 31/114 | 22/111 | 33/111 | 39/345 |
| DiarrhoeaGastrointestinal disorders | 19/113 | 19/114 | 23/111 | 17/111 | 34/345 |
| ArthritisMusculoskeletal and connective tissue disorders | 18/113 | 16/114 | 21/111 | 18/111 | 47/345 |
| SinusitisInfections and infestations | 21/113 | 11/114 | 15/111 | 17/111 | 34/345 |
| Urinary tract infectionInfections and infestations | 18/113 | 16/114 | 18/111 | 20/111 | 33/345 |
| Oedema peripheralGeneral disorders | 13/113 | 15/114 | 18/111 | 15/111 | 41/345 |
| Age Continuous(years) | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Total |
|---|---|---|---|---|---|
| Mean | 42.2 ± 10.9 | 42.0 ± 11.7 | 42.6 ± 10.7 | 41.8 ± 11.7 | 42.2 ± 11.2 |
| Sex: Female, Male(Participants) | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Total |
|---|---|---|---|---|---|
| Female | 102 | 107 | 105 | 105 | 419 |
| Male | 11 | 7 | 6 | 6 | 30 |
| Region of Enrollment(participants) | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Total |
|---|---|---|---|---|---|
| United States | 113 | 113 | 111 | 109 | 446 |
| Canada | 0 | 1 | 0 | 2 | 3 |
The record gives a start of Oct 2003, a primary completion of Aug 2005 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 7 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →